37 1. Abstract 38 Cardiopulmonary testing (CPET) and biomarkers such as reactive protein (CRP) have shown great promise for characterizing the heart failure (HF) 40 phenotypes. However, the underlying metabolic changes that cause, predict and accompany 41 changes in these parameters are not well known. In depth knowledge of these metabolic changes 42 has the ability to provide new insights towards the clinical management of HF as well as providing 43 better biomarkers for the assessment of disease progression and measurement of success from 44 clinical interventions. To address this knowledge gap, we undertook a deep metabolomic and 45 lipidomic phenotyping of a cohort of HF patients and utilized Multiple Regression Analysis 46 (MRA) to identify associations between the patient's plasma metabolome and the lipidome to 47 parameters of CPET and the above mentioned HF biomarkers (HFBio). A total of 49 subjects were 48 submitted to CPET and HFBio evaluation with deep metabolomic and lipidomic profiling of the 49 plasma. Stepwise MRA and Standard Least Squares methods were used to determine models of 50 best fit. Metabolic Pathway Analysis was utilized to detect what metabolites were over-represented 51 and significantly enriched, and Metabolite Set Enrichment Analysis was used to explore pre-52 existing biological knowledge from studies of human metabolism. The study cohort was 53 predominantly males of African American decent, presenting a high frequency of diabetes, 54 hyperlipidemia, and hypertension with a low mean left ventricular ejection fraction and a high left 55 ventricular end-diastolic and end-systolic volume. VE/VCO2 and Peak VO2 (CV=0.07 and 0.08, 56 respectively) showed the best metabolic predictive model for test performance, while CRP and 57 NT-ProBNP (CV=0.31 and 0.29, respectively) were the least fitted models. Aminoacyl-tRNA and 58 amino acid biosynthesis, amino acid metabolism, nitrogen metabolism, pantothenate and CoA 59 biosynthesis, sphingolipid and glycerolipid metabolism, fatty acid biosynthesis, glutathione 60 metabolism, and pentose phosphate pathway (PPP) were revealed to be the most relevant 61 pathways. Principal related diseases were brain dysfunction and enzyme deficiencies associated 62 with lactic acidosis. Considering the modulations in HF poor test performance, our results indicate 63 an overall profile of oxidative stress, lactic acidosis, and metabolic syndrome coupled with 64 mitochondria dysfunction. Overall, the insights resulting from this study's MRA coincides with 65 what has previously been discussed in parts in existing literature thereby confirming the validity 66 of our findings while at the same time thoroughly characterizing the metabolic underpinning of 67 CPET and HFBio results.
of MS-grade water. Upon vortexing (20s) the sample was centrifuged at 12,300 rpm for 2 min. 134 The upper organic phase was collected in two 300 µL aliquots and evaporated with a vapor trap. 135 Dried extracts were resuspended using 110 µL of a methanol/toluene (9:1, v/v) mixture containing 136 CUDA (50 ng/ml; internal standard for quality control of injection) with support of vortexing (10 137 s), and centrifuged at 800 rpm for 5 min, followed by transferring 100 uL of the supernatant into at 4°C using the Orbital Mixing Chilling/Heating Plate. Next, the mixture was centrifuged for 2min 146 at 14,000 rcf. 450μL of the supernatant was dried with cold trap concentrator. The dried aliquot 147 was then reconstituted with 450 μL acetonitrile:water (50:50) solution and centrifuged for 2 min 148 at 14,000 rcf. The supernatant was transferred to a polypropylene tube and subjected to drying in 149 a cold trap. The process of derivatization began with addition of 10 μL of 40 mg/mL 150 Methoxyamine hydrochloride solution to each dried sample and standard. Samples were shaken at 151 maximum speed at 30 o C for 1.5 hours. Then, 91 μL of MSTFA + FAME mixture was added to 152 each sample and standard and capped immediately. After shaking at maximum speed at 37 o C, the 153 content was transferred to glass vials with micro-serts inserted and cap immediately. 156 Untargeted lipid analysis was obtained with Sciex TripleTOF 6600 coupled to Agilent 1290 LC. 157 Lipids were separated on an Acquity UPLC CSH C18 column (100 × 2.1 mm; 1.7 µm) (Waters, 158 Milford, MA, USA). The column was maintained at 65 °C and the flow-rate of 0.6 mL/min. The 159 mobile phases consisted of (A) 60:40 (v/v) acetonitrile:water with 10 mM ammonium acetate and 160 (B) 90:10 (v/v) isopropanol:acetonitrile with 10 mM ammonium acetate. The separation was 161 conducted following a stepwise gradient: 0-2 min 15-30% (B), 2-2.5 min 48% (B), 2.5-11 min 162 82% (B), 11-11.5 min 99% (B), 11.5-12 min 99% (B), 12-12.1 15% (B), 12-14 min 15% (B). 163 Negative and positive electrospray ionization (ESI) modes were applied with nitrogen serving as 164 the desolvation gas and the collision gas. The parameters for detection of lipids were as follows: The injection volume was 1 μL in splitless mode at 250 °C. Electron impact ionization at 70V was 195 employed with an ion source temperature of 250°C. The scan mass ranged from 85 to 500 Da with 196 acquisition rate of 17 spectra/second. were presented as peak heights normalized by mTIC, a form of total ion chromatography with 202 authentic metabolites that discounts abiotic artifacts. A compound is normalized by taking an 203 individual peak height (mTICij) and dividing it by the product of average total peak heights and 204 the sum of the specific compounds' peak heights (mTICaverage x mTICsum,j). Using mTIC allows for 205 the merger of the two databases. Outliers were eliminated using the Interquartile range (IQR) from 206 a box-and-whisker plot with Turkey's method detecting outliers as any value for the determined 207 test outside of 1.5 times the IQR [21] . Metabolic data were filtered to exclude detected prescribed 208 drugs, and from the lipidomic data only phospholipids, with detected fatty acids composition, were 209 used in the analysis. 210 We utilized stepwise multiple regression analysis and Standard Least Squares methods to 211 identify the set of metabolites which best associated with measures of cardiorespiratory fitness 212 (peak oxygen consumption, oxygen uptake efficiency slope, exercise duration, VE/VCO2 slope) 
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MRA method was applied using the forward selection to enter the terms with the lowest p-219 values, allowing that at each step the candidate variable that increased the adjusted R 2 the most 220 was selected, until the model reached an adjusted R 2 ≥ 0.8 and all the predictors had a statistically 221 significant effect (p<0.05). All models reached a statistical significance of p<0.001. After the 222 selection of predictors, the different models were standardized by mean centering to allow for the 223 comparison of their coefficients, and the mean response of their dependent variables was 
Results
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The study cohort included mostly African Americans with diabetes, hyperlipidemia, and 247 hypertension ( Table 1) . The predictors of HF tests performance are listed in Table 2 . The 248 standardized regression coefficients suggest the expected elevation or decrease of lipids and 249 metabolites in plasma based in their positive or negative values, although values higher than 0.3 250 were considered more reliable to indicate metabolic modulation.
251
From the regression models it was possible to estimate the mean response of CPET and 252 HFBio ( Table 3 ) and compare them with threshold references published by other authors. The 253 relative proximity of the tests mean response to these published threshold values indicates that 254 metabolic modulation can indeed be assessed by HF tests performance. To be able to compare 255 models we used the coefficient of variance, where the model with the smaller CV has predicted 256 values that are closer to the actual values. VE/VCO2 and Peak VO2 (CV=0.07 and 0.08, 257 respectively) showed the best metabolic predictive model for test performance. Galectin-3 258 (CV=0.13) also showed a reasonable predictive model, while CRP and NT-ProBNP (CV=0.31 and 259 0.29, respectively) were the least fit models.
260
The diverse metabolites and lipids species compounding the CPET and HFBio prediction 261 models are suggestive of the metabolic profile of the HF patient's cohort. Therefore, they were 262 used in the pathway enrichment analysis to indicate the more significant pathways impacting the 263 prediction of HF patient's performance. Figure 2 shows that 13 pathways are significantly 264 involved in prediction of HF test performance. Aminoacyl-tRNA and amino acid biosynthesis, 265 amino acid metabolism, nitrogen metabolism, pantothenate and CoA biosynthesis, along with 266 sphingolipid and glycerolipid metabolism, fatty acid biosynthesis, as well as glutathione 267 metabolism and pentose phosphate pathway were revealed as the more relevant pathways.
268
To explore the similarity of other diseases metabolic dysfunction to HF metabolic 269 modulation, a pathway enrichment analysis was utilized (Figure 3) . This analysis revealed 14 270 disorders statistically significant and with high impact that demonstrated similar metabolic 271 perturbation to that observed by us for HF. Most of these identified diseases were related to brain [37] . 344 Pro-inflammatory and pro-oxidant effects were not the only physiological attributes we 345 found. Our study also revealed that phenylethanolamine metabolism also was affected in poor 
